The CHA(2)DS(2)-VASc score predicts chronic kidney disease among patients with atrial fibrillation

doi:10.1007/s11255-020-02514-x

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24496

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24496

Title:	The CHA(2)DS(2)-VASc score predicts chronic kidney disease among patients with atrial fibrillation
Authors:	Wang, CJ;Hsieh, YP;Kor, CT;Chiu, PF
Keywords:	Chronic kidney disease (CKD);End-stage renal disease (ESRD);Atrial fibrillation (AF);CHA(2)DS(2)-VASc score
Date:	2020
Issue Date:	2022-08-09T08:03:17Z (UTC)
Publisher:	SPRINGER
ISSN:	0301-1623
Abstract:	Background It is unclear how the CHA2DS2-VASc score can predict subsequent chronic kidney disease (CKD) and end-stage renal disease (ESRD) among atrial fibrillation (AF) patients. Methods We identified incident AF patients without CKD between 2000 and 2013 from the National Health Insurance Research Database (NHIRD) of Taiwan and calculated the CHA(2)DS(2)-VASc score for each patient. Adjusted hazard ratio (HR) with 95% confidence interval (CI) was estimated from multivariate cause-specific Cox models to assess the risk of CKD and ESRD associated with the CHA(2)DS(2)-VASc score. Results A total of 8764 participants with AF who did not have CKD were included in the analysis. The mean age was 69.63 +/- 13.48 years and 4800 (54.8%) were males. The adjusted HR of CKD displayed a stepwise increase with the increase in the CHA(2)DS(2)-VASc score. When compared with those with a CHA(2)DS(2)-VASc score of 0, the adjusted HRs of CKD were 1.57 (95% CI 1.09-2.26), 2.04 (95% CI 1.42-2.94), 2.48 (95% CI 1.70-3.62), 2.88 (95% CI 1.95-4.26), 3.29 (95% CI 2.18-4.95) and 4.00 (95% CI 2.61-6.13) for the AF patients with a CHA(2)DS(2)-VASc score of 1, 2, 3, 4, 5 and >= 6, respectively. Similarly, as the CHA(2)DS(2)-VASc score increased, the adjusted HR of ESRD showed a gradual increase. Conclusions Patients with a higher CHA(2)DS(2)-VASc score were linked to a higher risk of CKD and ESRD in a dose-dependent effect, i.e. the incidence of CKD/ESRD increased with the increasing CHA(2)DS(2)-VASc score.
URI:	http://dx.doi.org/10.1007/s11255-020-02514-x https://www.webofscience.com/wos/woscc/full-record/WOS:000537379800004 https://ir.csmu.edu.tw:8080/handle/310902500/24496
Relation:	INTERNATIONAL UROLOGY AND NEPHROLOGY ,2020 ,v52 ,issue 8 ,p1523-1531
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	239	View/Open

Loading...